In order to investigate the effects of the different treatment modalities on malignant potential and propensity towards worse outcomes, we subjected tumor cells to FACS analysis of CD44, a marker for cancer-initiating cells [37]–[39]. This evidence concerns the gene CD44 and neoplasm.